Posted by Michael Wonder on 03 May 2021
Chiesi Global Rare Diseases announces FDA approval of Ferriprox (deferiprone) for treatment of transfusional iron overload due to sickle cell disease
1 May 2021 - Approval is based on demonstrated reduction in liver iron concentration.
Chiesi Global Rare Diseases announced today that the U.S. FDA has approved Ferriporox (deferiprone) for the treatment of transfusional iron overload due to sickle cell disease or other anemias in adult and paediatric patients 3 years of age and older.
